Highlights Fractyl Health, Inc.

Equities

GUTS

US35168W1036

Market Closed - Nasdaq Other stock markets 01:30:00 29/06/2024 am IST			5-day change	1st Jan Change
4.27 ^USD	-3.61%		-5.32%	0.00%

24/06	Fractyl Health, Inc. Announces Advancement in Weight Maintenance Pipeline and Business Updates	CI
24/06	Fractyl Health Says Potential Diabetes, Obesity Treatment Performed Well in Preclinical Trial	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Fractyl Health, Inc. Announces Advancement in Weight Maintenance Pipeline and Business Updates	24/06	CI
Fractyl Health Says Potential Diabetes, Obesity Treatment Performed Well in Preclinical Trial	24/06	MT
Fractyl Health, Inc. Presents New Preclinical Data on Sustained Weight Maintenance and Improved Body Composition from its Rejuva® Single-Administration GLP-1 Pancreatic Gene Therapy at the American Diabetes Association?s 84th Scientific Sessions	23/06	CI
Fractyl Health, Inc. Presents Compelling Preclinical Data from Single-Administration GLP-1 Pancreatic Gene Therapy Rejuva At Digestive Disease Week 2024	20/05	CI
Earnings Flash (GUTS) FRACTYL HEALTH Reports Q1 Revenue $33,000	14/05	MT
Fractyl Health, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05	CI
Fractyl Health Says New Revita Data Show Sustained Weight Loss, Glucose Control in Type 2 Diabetes	13/05	MT
Fractyl Health Presents Clinical Update on Revita German Real-World Registry for Patients With Advanced Type 2 Diabetes	13/05	CI
Signs of Softening Inflation Fuel Narrow Premarket Gains for US Equity Futures	01/04	MT
Rising Rate Cut Hopes Buoy Exchange-Traded Funds, Equity Futures Pre-Bell Monday	01/04	MT
Top Premarket Decliners	01/04	MT
Fractyl Health Shares Drop After Wider 4Q Loss	01/04	DJ
Earnings Flash (GUTS) FRACTYL HEALTH Posts Q4 Revenue $7,000	01/04	MT
Fractyl Health, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	01/04	CI
Fractyl Health, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01/04	CI
Fractyl Health Shares Rise 40% After FDA Approval of IDE for Revita	01/04	DJ
Fractyl Health, Inc. Receives FDA IDE Approval for the Revita®? Remain-1 Pivotal Study of Weight Maintenance in Obesity After Discontinuation of GLP-1 Based Drugs	01/04	CI
Fractyl Health Reports 'Promising' Preclinical Findings From Rejuva Platform; Shares Fall	12/03	MT
Fractyl Health Announces New Results from Its Rejuva® Platform Demonstrating Potent and Durable Effects of A Single Dose of A Human Glp-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the Db/Db Mouse Model of Diabetes and Obesity	12/03	CI
Fractyl Health, Inc. has completed an IPO in the amount of $109.999995 million.	01/02	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Fractyl Health, Inc.

Equities

GUTS

US35168W1036

Highlights

Filters